Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first-quarter ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Pfizer's stock rallies after drug giant cites strength in its COVID-19 drugs and Vyndaqel heart medication Pfizer Inc.'s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit ...

In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to ...

Shares of Pfizer fell Wednesday after the drugmaker forecast 2024 revenue and profit below Wall Street's expectations, as it sees weak demand for its once-blockbuster Covid products. Pfizer also ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects. Sales of ...

Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped estimates, even as the company's sales fell, largely due to dwindling revenue for its antiviral Covid ...

Pfizer profits dipped on lower sales of Paxlovid - Copyright AFP/File Patrick T. Fallon Pfizer profits dipped on lower sales of Paxlovid - Copyright AFP/File Patrick ...